Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Weltermann, Ansgar  [Clear All Filters]
2024
Nikoloudis A, Buxhofer-Ausch V, Aichinger C, Binder M, Hasengruber P, Kaynak E, Wipplinger D, Milanov R, Strassl I, Stiefel O, et al. Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion. Cytotherapy. 2024.
2023
Nikoloudis A, Neumann IJulia, Buxhofer-Ausch V, Machherndl-Spandl S, Binder M, Kaynak E, Milanov R, Nocker S, Stiefel O, Strassl I, et al. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients-A Retrospective Single-Center Analysis. Vaccines (Basel). 2023;11(10).
Strassl I, Windhager A, Machherndl-Spandl S, Buxhofer-Ausch V, Stiefel O, Weltermann A. TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer. J Cancer Res Clin Oncol. 2023.
2022
Machherndl-Spandl S, Vockenhuber T, Binder M, Weltermann A, Apfalter P, Lass-Flörl C, Girschikofsky M. Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia. Leuk Lymphoma. 2022:1-6.
2021
Nikoloudis A, Wagner H, Machherndl-Spandl S, Buxhofer-Ausch V, Strassl I, Stiefel O, Wipplinger D, Milanov R, Kaynak E, Hasengruber P, et al. Relapse protection following early CMV reactivation after HSCT is limited to HLA-C KIR ligand homozygous recipients. Transplant Cell Ther. 2021.
2016
Sperr WR, Zach O, Pöll I, Herndlhofer S, Knoebl P, Weltermann A, Streubel B, Jaeger U, Kundi M, Valent P. Karyotype plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) who Benefit from Intensive Post-Induction Consolidation Therapy. Am J Hematol. 2016.